Corcept Therapeutics (CORT)

$41.16 0.24 (0.59%)

12:47 EDT CORT Stock Quote Delayed 30 Minutes

CORT Stock Earnings: Corcept Therapeutics Beats EPS, Beats Revenue for Q2 2024

By InvestorPlace Earnings Jul 29, 2024

CORT stock results show that Corcept Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

7 Biotech Stocks to Boost Your Portfolio to Peak Health

Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for June 2024

CORT Stock Earnings: Corcept Therapeutics Beats EPS, Beats Revenue for Q1 2024

Volume:

Previous Close -

Market Cap 4.77B

PE Ratio 36.42

EPS 1.13

Volume (Avg. Vol.) 526,124

Day's Range $40.62 - $41.69

52-Week Range $20.87 - $43.74

Dividend & Yield N/A (N/A)

CORT Stock Predictions, Articles, and Corcept Therapeutics News

7 Underappreciated Biotech Stocks to Pick Up on the Cheap

By Josh Enomoto, InvestorPlace Contributor Nov 9, 2023

Amid some rising questions for the economy, value-seeking investors may want to consider underappreciated biotech stocks. As a sector that, while not immune to broader…

7 Undervalued Biotech Stocks to Buy Before They Boom

By Josh Enomoto, InvestorPlace Contributor Dec 29, 2022

While medical innovations offer tremendous appeal, investors can still get a discount in this sector via undervalued biotech stocks to buy.

Our 7 Top Biotech Stock Picks for 2023

By Josh Enomoto, InvestorPlace Contributor Dec 9, 2022

Following the devastation of Covid-19, there’s greater interest toward medical innovations, thus bolstering biotech stock picks for 2023.

7 Under-the-Radar Stocks With 100% Upside Potential

By Will Ashworth, InvestorPlace Contributor Oct 17, 2022

If you're looking for under-the-radar stocks in the current market environment, you're likely to find many imposters so tread carefully.

3 Biotech Stocks Outperforming a Bear Market

By Jaimini Desai Jul 15, 2022

These biotech stocks are the most attractive from a valuation and growth perspective as they are less impacted by a slowing economy or change in monetary policy.

Pharma Stocks: Why Corcept Therapeutics Stock Is Soaring 24% Today

By William White, InvestorPlace Writer Nov 19, 2020

Corcept Therapeutics (CORT) is leading pharma stocks news on Thursday with approval from the U.S. Patent and Trademark Office's PTAB.

7 Great Biotech Stocks to Buy and Hold Now

By Chris Markoch, InvestorPlace Contributor Jun 11, 2020

As investors begin to turn their attention away from Covid-19 and the novel coronavirus, these biotech stocks present excellent opportunities.

FDA Shame List: 40 Drug Makers That Try to Block Generic Drugs

By Karl Utermohlen, InvestorPlace Writer May 18, 2018

The Food and Drug Administration (FDA) announced a list of drug makers that have tried to block generic drugs in its new shame list. Here they are.

10 Healthcare Stocks to Stave Off the Market Flu

By Louis Navellier, Editor, Growth Investor Apr 6, 2018

One thing is certain, healthcare isn’t going away.

Plains GP Holdings LP (PAGP) and Green Plains Inc (GPRE) Lead Today’s Top 11 Investor Filings

By Fintel Jun 15, 2017

13D and 13G filings are windows on activist investor activity. Today we focus on Plains GP Holdings LP, Green Plains Inc and 9 other filings

7 Healthcare Stocks With A-Rated Prospects

By Louis Navellier, Editor, Growth Investor Apr 21, 2017

An Obamacare replacement is back in the news, and these seven A-rated healthcare stocks are winners regardless of how it shakes out.

Corcept Therapeutics (CORT)

CORT Stock Earnings: Corcept Therapeutics Beats EPS, Beats Revenue for Q2 2024

7 Biotech Stocks to Boost Your Portfolio to Peak Health

Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for June 2024

CORT Stock Earnings: Corcept Therapeutics Beats EPS, Beats Revenue for Q1 2024

Top 5 Stocks for 2024

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

Corcept Therapeutics (CORT)

Top 5 Stocks for 2024

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

CORT Stock Predictions, Articles, and Corcept Therapeutics News

Subscriber Sign in